Theragen has received its second patent in three months for its ActaStim-S post-op spine fusion and bone growth stimulation device.
The patent protects ActaSim's design that allows surgeons to use it with ease.
"Receiving the patent is important. It's also validating seeing the AcatStim-S design so well received by patients and surgeons," Chris McAuliffe, Theragen's CEO, said in an Oct. 4 press release. "Our first patent focused on device connectivity, while this patent protects our device design. ActaStim-S offers significant practical advantages versus large, obtrusive devices that can constrain ambulation and mobility."